...
首页> 外文期刊>Clinical and Translational Gastroenterology >Accuracy and Safety of 1,055 Transjugular Liver Biopsies in Postliver Transplant Patients
【24h】

Accuracy and Safety of 1,055 Transjugular Liver Biopsies in Postliver Transplant Patients

机译:1,055次突厥肝活检患者的准确性和安全性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: The purpose of this study was to investigate the rates of complications and diagnostic yield of transjugular liver biopsy (TJLB) in deceased donor liver transplant (DDLT) recipients. METHODS: From January 2009 to December 2019, 1,055 TJLBs were performed in 603 adult DDLT recipients with a mean age of 54 (±12 years). Data were retrospectively reviewed to determine the diagnostic efficacy and incidence of major and minor complications in the 3-day and 1-month period after TJLB. In addition, data were stratified according to platelet count and international normalized ratio to determine the safety of TJLB in patients with varying degrees of coagulopathy. RESULTS: TJLB yielded diagnostic rate of 98.1% (1,035/1,055), with an overall complication rate of 8.3% (88/1,055). Major complications accounted for 0.85% (9/1,055), and minor complications occurred in 7.48% (79/1,055). When patients were stratified by platelet count (0–50, 51–100, 101–200, 201–300, and &300 × 10 ~(3) platelets/μL), no significant difference was noted in complication rates (9.5%, 8.6%, 7.6%, 8.5%, and 10.7%, respectively). When grouped by international normalized ratio (0–1, 1.1–2.0, 2.1–3.0, and &3.0), there was no statistical difference in complication rates (8.3%, 8.5%, 7.7%, and 0%, respectively). DISCUSSION: TJLB is a safe, adequate, and effective method to investigate hepatic disorders in DDLT recipients with severe coagulopathy.
机译:介绍:本研究的目的是探讨死亡的供体肝移植(DDLT)接受者中的Transjugular肝活组织检查(TJLB)的并发症和诊断产量。方法:2009年1月至2019年12月,在603名成人DDLT接受者中进行了1,055吨,平均年龄为54(±12年)。回顾性地审查了数据,以确定TJLB后3天和1个月的主要和次要并发症的诊断疗效和发病率。此外,根据血小板计数和国际标准化比例分层,以确定TJLB在不同程度的凝血病变的患者中的安全性。结果:TJLB产生98.1%(1,035 / 1,055)的诊断率,整体并发症率为8.3%(88 / 1,055)。主要并发症占0.85%(9 / 1,055),少量并发症7.48%(79 / 1,055)。当患者通过血小板计数(0-50,51-100,101-200,201-300和& GT; 300×10〜(3)血小板/μl),并发症率没有显着差异(分别为9.5%,8.6%,7.6%,8.5%和10.7%)。当通过国际归一化比率进行分组(0-1,1.1-2.0,2.1-3.0和& 3.0),并发症率没有统计学差异(8.3%,8.5%,7.7%和0%) )。讨论:TJLB是一种安全,充分,有效的方法,用于调查具有严重凝血病的DDLT受体中的肝疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号